Dr. Bosch To Review DCVax®
Portfolio Of Products For All Solid Tumor Cancers

BETHESDA, Md., Jan. 29, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for cancer,
announced today that Dr. Marnix Bosch, the Company’s Chief
Technical Officer, will be presenting at the Phacilitate Cell And
Gene Therapy Forum 2013, today at 3:30 pm in a session entitled
Clinical Development Updates: Oncology.  The conference is
being held at the Grand Hyatt Hotel at 10th and H Street in
downtown Washington, D.C., and is a leading multi-disciplinary
gathering relating to new medical technologies involving cell
therapies.

Dr. Bosch’s presentation is entitled Dendritic Cell
Immunotherapy for Cancer – The Northwest Biotherapeutics
Portfolio.  He will be describing the Company’s three distinct
product lines, which are all based upon the Company’s DCVax®
platform technology using dendritic cells (DCs), the master cells
of the immune system, to mobilize a patient’s whole immune system
to attack that patient’s cancer in a powerful but non-toxic
manner.  Dr. Bosch will discuss the Company’s lead program,
with its DCVax®-L product in a 300-patient Phase III
clinical trial for brain cancer, and he will also discuss the
Company’s latest program, with DCVax®-Direct in a Phase I/II
trial for all solid tumor cancers (cancers in any tissues) which
are inoperable.

“We are pleased to participate in this year’s Phacilitate
conference, to describe the strong progress of our clinical
programs with two different immune therapy products which are
applicable to all solid tumor cancers,” commented Linda Powers, CEO
of NW Bio.  “This multi-disciplinary gathering of scientific,
medical, business and regulatory parties provides a unique forum
for highlighting the multi-faceted strengths of our DCVax®
products, including their scientific foundations, clinical
significance, ease of administration and cost
effectiveness.” 

DCVax®-Direct is NW Bio’s third product line.  It
offers a potential new treatment option for a particularly severe
unmet medical need:  the wide range of clinical situations in
which patients’ tumors are considered “inoperable” because the
patient has multiple tumors, or their tumor cannot be completely
removed, or the surgery would cause undue damage to the patient and
impair their quality of life.  For these patients, the outlook
today is bleak and survival remains quite limited.

When DCVax®-Direct was administered in pre-clinical
animal studies, existing tumors regressed.  Importantly, the
tumors that regressed included not only tumors that were injected
with DCVax®-Direct but also tumors on the opposite side of
the animal’s body which were not injected, indicating a systemic
immune response.  Further, when the animals were subsequently
challenged (i.e., injected) with cancer cells, the animals did not
re-develop cancer, indicating immune memory.  The Company’s
proprietary activation step for the dendritic cells was key to
these striking results.

DCVax®-Direct is based upon the same platform technology
as the Company’s first two major product lines: DCVax®-L and
DCVax®-Prostate.  Each product line involves two key
ingredients:  the dendritic cells (which are activated to
mobilize the immune system to attack the patient’s cancer), and
biomarkers of the patient’s tumor (which identify the targets for
the immune system to attack).  

The Company’s first product line, DCVax®-L, is
potentially applicable for all solid tumor cancers in which the
tumors can be surgically removed.  DCVax®-L is
currently in a 300-patient randomized Phase III clinical trial for
Glioblastoma multiforme brain cancer in both Europe and the United
States. 

The Company’s second product line, DCVax®-Prostate, is for
hormone independent prostate cancer, and has previously been
cleared by the FDA for a 612-patient randomized Phase III clinical
trial.  The Company plans to enter into a partnership in order
to proceed with this Phase III trial program.  

For further information about the Company and its programs,
please visit the Company’s website at www.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
United States and Europe.  The Company has a broad platform
technology for DCVax® dendritic cell-based vaccines.  The
Company’s lead program is a 300-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM).  GBM is the most
aggressive and lethal brain cancer.  The Company also
previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer, and clearance from the FDA for Phase
I/II trials in multiple other cancers.  The Company has also
conducted a Phase I/II trial with DCVax® for metastatic ovarian
cancer. 

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
with GBM and other cancers  using DCVax® and future clinical
trials, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.  Words such
as “expect,” “believe,” “intend,” “plan,” “continue,” “may,”
“will,” “anticipate,” and similar expressions are intended to
identify forward-looking statements.  Actual results may
differ materially from those projected in any forward-looking
statement.  Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as the Company’s ability to raise
additional capital, risks related to the Company’s ability to
enroll patients in its clinical trials and complete the trials on a
timely basis, the uncertainty of the clinical trials process,
uncertainties about the timely performance of third parties, and
whether the Company’s products will demonstrate safety and
efficacy.  Additional information on these and other factors,
including Risk Factors, which could affect the Company’s results,
is included in its Securities and Exchange Commission (“SEC”)
filings.  Finally, there may be other factors not mentioned
above or included in the Company’s SEC filings that may cause
actual results to differ materially from those projected in any
forward-looking statement.  You should not place undue
reliance on any forward-looking statements.  The Company
assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as
required by securities laws.